Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Long-Term Debt
Zealand Pharma A/S
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Long-Term Debt
kr375.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
37%
|
CAGR 10-Years
3%
|
|
|
Genmab A/S
CSE:GMAB
|
Long-Term Debt
kr937m
|
CAGR 3-Years
37%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Long-Term Debt
€365.1m
|
CAGR 3-Years
55%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Long-Term Debt
kr86.7m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
10%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Long-Term Debt
kr7.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
56%
|
|
|
Saniona AB
STO:SANION
|
Long-Term Debt
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Long-Term Debt?
Long-Term Debt
375.7m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Long-Term Debt amounts to 375.7m DKK.
What is Zealand Pharma A/S's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
3%
Over the last year, the Long-Term Debt growth was 266%. The average annual Long-Term Debt growth rates for Zealand Pharma A/S have been -21% over the past three years , 37% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet